Is dabigatran considered a cost-effective alternative to warfarin treatment: a review of current economic evaluations worldwide. [electronic resource]
Producer: 20140303Description: 845-58 p. digitalISSN:- 1941-837X
- Anticoagulants -- adverse effects
- Atrial Fibrillation -- drug therapy
- Benzimidazoles -- administration & dosage
- Cost-Benefit Analysis
- Dabigatran
- Embolism -- prevention & control
- Hemorrhage -- chemically induced
- Humans
- Quality-Adjusted Life Years
- Stroke -- prevention & control
- Warfarin -- administration & dosage
- beta-Alanine -- administration & dosage
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review
There are no comments on this title.
Log in to your account to post a comment.